SCHEMBL20575561

SCHEMBL20575561

Fc1cc(N2C=C3CCCN3C2c2ccc3ncsc3c2)cc(F)c1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.35
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
TGFBR1 P36897 1/20 0.34
HSD11B1 P28845 1/20 0.33
LMNA P02545 1/20 0.32
CYP3A4 P08684 1/20 0.32
GAA P10253 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
HTT P42858 1/20 0.32
DPP4 P27487 1/20 0.32
DPP8 Q6V1X1 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.31
KDM4E B2RXH2 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
HKDC1 Q2TB90 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20575191 0.91 SLC6A2 (0.34) KDM1ASLC6A2SLC6A4SLC6A3HSD11B1
SCHEMBL20575667 0.89 KDM1A (0.35) KDM1ASLC6A2SLC6A4SLC6A3HSD11B1
SCHEMBL20575901 0.88 SLC6A2 (0.33) KDM1ASLC6A2SLC6A4SLC6A3TGFBR1
SCHEMBL20575637 0.86 NPC1 (0.36) KDM1ASLC6A2SLC6A4SLC6A3HSD11B1
SCHEMBL20575563 0.86 KDM1A (0.34) KDM1ASLC6A2SLC6A4SLC6A3TGFBR1
SCHEMBL20576481 0.83 KDM1A (0.33) KDM1ASLC6A2SLC6A4SLC6A3HSD11B1
SCHEMBL20575587 0.82 SLC6A2 (0.34) KDM1ASLC6A2SLC6A4SLC6A3TGFBR1
SCHEMBL20575589 0.82 TGFBR1 (0.35) KDM1ASLC6A2SLC6A4SLC6A3TGFBR1
SCHEMBL20575162 0.82 NPC1 (0.38) SLC6A2SLC6A4SLC6A3HSD11B1LMNA
SCHEMBL20575188 0.81 SLC6A2 (0.34) SLC6A2SLC6A4SLC6A3TGFBR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10696693-B2 Fused imidazole derivatives as TGF-beta inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2020-06-30 US disclosed
US-20180346487-A1 Fused Imidazole Derivatives as TGF-Beta Inhibitors MIDCAP FINANCIAL TRUST 2018-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10696693-B2 Fused imidazole derivatives as TGF-beta inhibitors TGFBR1, TGFBR2, SMAD3 KDM1A 384/4885SLC6A2 3506/4885SLC6A4 3203/4885
US-20180346487-A1 Fused Imidazole Derivatives as TGF-Beta Inhibitors TGFBR1, TGFBR2, SMAD3 KDM1A 384/4885SLC6A2 3506/4885SLC6A4 3203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.